ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Reducing Lead Time & Optimizing Costs

  Explore how the use of this component platform produces significant savings, reduces elastomer SKU complexity, and increases speed to market.

• Advances In Spray Drying For Enhanced Bioavailability And Improved Formulation Control

  In a recent webinar, Lonza discussed the process it uses to develop a spray dried powder formulation and scale from early feasibility studies to manufacturing.

• Selecting A Vial Container Closure System With The DeltaCube™ Modeling Platform

  Understand a system approach that facilitates data-driven selection and optimization of vial container closure system components.

• Unlocking The Promise Of NAMs

  Human-relevant models are reshaping safety and efficacy decisions, but impact depends on selecting the right tools, integrating evidence, and turning complex data into clear, decision‑ready insights.

• Avoiding The Pitfalls Of LNPs And Complex Formulations

  Explore the necessary components of a smooth tech transfer for LNP-based drugs, including the variables that impact LNP formulation and the outsourcing strategies needed to avoid common pitfalls.

• Q&A: Navigating PFAS In Medical Devices

  Explore how PFAS in medical devices pose environmental and health concerns, prompting regulatory scrutiny.

• Vial Containment Systems Based On Elastomer 4031/45 Gray

  Examine the results of two, two-year studies that indicate good container closure integrity performance that can be achieved with stoppers of a given elastomer, independent of configuration.

• Flexibility And Capability In Pre-Filled Syringes: The Future Of PFS

  Outlined here are the inherent benefits of PFS and how they relate to the delivery of drugs, such as biologics and vaccines, how SARS-CoV-2 could be fueling an explosive increase in PFS demand, and how a partnership with a flexible CDMO is the key to success.

• Liquid Capsule Manufacturing: What To Know

  Capsules surround a drug in an unflavored, solid barrier enclosure. This article focuses on liquid capsule manufacturing and its advantages.

• Formulation Development Strategy For Early Phase Human Studies

  Determining bioavailable formulation for animal PK, GLP toxicity, first-in-human, and first-in-patient is challenging. Drug delivery systems are usually used for poorly soluble and bioavailable compounds.